BILLERICA, MA / ACCESSWIRE / November 18, 2020 / Nuvera Fuel Cells, LLC, a provider of fuel cell power solutions for motive applications, announced the commercial availability of the Nuvera® E-60 Fuel Cell Engine, the latest addition to the E-series family of compact, efficient, and reliable solutions for vehicle electrification.

With Nuvera's latest high-performance fuel cell stacks at its core, the E-60 engine model enables electrified powertrains for material handling equipment, buses, trucks, and other on- and off-road vehicles. Building on the design of the E-45 engine released earlier this year, the E-60 model provides 59 kW net output power (67 kW gross power) to help OEMs meet increasing vehicle performance demands and market requirements, broadening the range of applications that can benefit from fuel cell power.

"We're at a pivotal moment in the transportation industry and OEMs are under pressure to create zero-emission vehicles that meet the operational standards of today's highest performing platforms," said Warren Brower, Chief Commercial Officer at Nuvera. "Fuel cells are the only answer to meet the functional requirements for many medium and heavy-duty applications, and our E-60 engine expands the options available to customers for higher power requirements."

The E-60 model includes its own fully integrated compressor and patented control logic for optimized operation. In addition, Nuvera E-Series fuel cell engines leverage the company's unique fuel cell stack technology that enables low operational cost, compactness, and durability. Nuvera's E-45 and E-60 fuel cell engines both provide freeze start capability.

Nuvera fuel cell engines are manufactured on the company's series-production lines at its US headquarters. Nuvera applications development teams provide exceptional local and remote vehicle integration support to customers in the U.S., Europe, and China.

ABOUT NUVERA FUEL CELLS, LLC
Nuvera Fuel Cells, LLC is a manufacturer of heavy-duty, zero-emission engines for mobility applications. With facilities located in the U.S. Europe, and China. Nuvera provides clean, safe, and efficient products designed to meet the rigorous needs of industrial vehicles and other transportation markets.

Nuvera is a subsidiary of Hyster-Yale Group, Inc., which designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks and aftermarket parts marketed globally primarily under the Hyster® and Yale® brand names. Hyster-Yale Group is a wholly owned subsidiary of Hyster-Yale Materials Handling, Inc. (HY). Hyster-Yale Materials Handling, Inc. and its subsidiaries, headquartered in Cleveland, Ohio, employ approximately 7,600 people worldwide.

CONTACT
Olivia Martin
omartin@mower.com
781.353.7002

SOURCE: Nuvera

ReleaseID: 617236

MIAMI, FL / ACCESSWIRE / November 18, 2020 / Since the launch of its new product "Monetize" the new digital company iMonetize, a subsidiary of Zürtech, has already done more for innovation in its industry than most companies have ever thought about.

Nick Perzichilli, Co-Founder and CEO of Zürtech AG

Up until this point data monetization platforms are highly utilized for data insights and recommendations, co-branding, co-registration or email captures to build your brands mailing list. All that is changing thanks to iMonetize who is disrupting traditional monetization models by leveraging a brand's customer acquisitions allowing any commerce brand to acquire another transaction in real-time or post-purchase. An impressive offering for any commerce brand to leverage valuable data that's sitting un-monetized inside a CRM or customer vault. 

Enter Switzerland-based Zürtech, and its brand iMonetize who are quickly winning a reputation in working with top brands to become disruptive forces in their markets. Most recently, this has led to iMonetize announcing a new strategic partnership with the Google Accelerator Program to power their product "Monetize".

Rebecca Selznick, A Senior Google account representative recently said, "We know that all Zürtech brands such as iMonetize are crazy growth engines."

"We are absolutely honored to have been hand-selected by the most powerful company of our generation, and to have a true partner in Google to power our products," said Nick Perzichilli, iMonetize Co-Founder.

iMonetize now has access to Google's top tools and resources, including things like one-on-one analytics, strategic support of Google Ad data, inventory, Fortune 100 level Google account representatives, proprietary information on customer behavior and much, much more. 

Experts from Google's digital marketing and strategy teams will work with the teams from iMonetize to manage and optimize Google Ad buys on their properties like Google Search, YouTube, and Display.

iMonetize uses its proprietary future proof technology to work seamlessly with a brand's existing online or offline commerce sales paths to dramatically boost bottom line profits from customer acquisitions in simple, effective ways that brands trust.

"iMonetize owes a lot of its success to Co-Founder Patrick Graf, who specializes in marketing-technology, compliance and payment processing and can manifest innovation as well as any of the top Fortune 100 CTOs," said Nick Perzichilli.

Within minutes iMonetize can deploy a powerful machine learning platform enabling any commerce brand to effectively manage their business objectives while intelligently mapping out the next best course of action for both the brand and its customers, and guarantees they'll generate your commerce brand an effortless recurring revenue stream, everytime.

"We work with many of the world's top online and offline commerce brands. While many of them excel at selling their core product, what they typically don't know about is monetization. The great thing about iMonetize is the fact that our customers fundamentally trust the platform, and are confident it works," said Mr. Perzichilli. 

Brands like HealthWidget that exploded from 0 to over 3 million customers in just 16 months are already using iMonetize widgets to monetize their e-commerce sales funnels in real-time. 

There are no business objectives incapable of being smashed with this proprietary monetization platform. Visit iMonetize.co today to join the World's fastest-growing brands that love iMonetize.

For more information and to learn more about Zürtech or iMonetize, go to Zurtech.ch or iMonetize.co

For business-related inquiries please contact David Brock at EVP@Zurtech.ch

Additional Links

Monetize – Commerce
Monetize – Post-Acquisition

SOURCE: Zürtech AG

ReleaseID: 617189

Majority of the Fortune 100 Supported by Trintech's Solutions

DALLAS, TX / ACCESSWIRE / November 18, 2020 / Trintech, a leading global provider of integrated Record to Report (R2R) software solutions for the office of finance, continues to be selected by enterprise organizations, including the majority of the Fortune 100, for its financial close software and expertise. Trintech's Cadency solution is the only System of Accounting Intelligence (SOAI) that combines end-to-end financial close activities into one streamlined process, including operational matching, intercompany transaction management, balance sheet reconciliations, journal entry management, close task management, and compliance.

"As the world continues to grapple with the effects of the pandemic, businesses are in need of real-time financial information and insight, which is critical to enabling businesses to make important financial decisions," said Michael Ross, Chief Product Officer at Trintech. "As a leading provider of financial software solutions, Trintech partners with businesses — offering the technology but also the functional expertise — to help them navigate the new ‘normal' of working remotely and accelerate the digitalization of their Finance functions."

Trintech announced the release of Cadency 9.0 earlier this year, which offers new, innovative support for transaction and account reconciliation, journal entry, systems integrations, artificial intelligence, and overall usability for large enterprises.

During Trintech Connect 2020's Enterprise User Conference on November 18th, Trintech is offering instructor-led product training sessions that will deep dive into its solutions, including Cadency. Attendees will have the ability to join interactive peer discussion groups and hear insights and updates from Trintech's CEO, Teresa Mackintosh, and other members of the executive team. Key topics include:

Fully automating administrative activities such as using account risk to determine the timing and processing of your reconciliations, transaction-based auto-certification, and updating account attributes.
Best practices and processes behind building effective match rules for real-life customer scenarios and the power of automating exception item processing
Using XML for automating balance and transaction loads, bulk reconciliations, UDFs, and reporting as well as how to use binders for a more efficient year-end audit
The key drivers of payment acceptance costs and identifying strategies and best practices to mitigate costs in both card-present and card, not present environments
Using Journal Entry (JE) for intercompany, automating the entire JE process from import to posting, and utilizing controls around the preparation, processing, and approving JEs

About Trintech

Trintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting, and bank fee analysis, to governance, risk and compliance – Trintech's portfolio of financial solutions, including Cadency® Platform, Adra® Suite, and targeted tools, ReconNET™, T-Recs®, and UPCS®, help manage all aspects of the financial close process. Over 3,500 clients worldwide – including the majority of the Fortune 100 – rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.

Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands, and the Nordics, as well as strategic partners in South Africa, Latin America, and the Asia Pacific. To learn more about Trintech, visit www.trintech.com, or connect with us on LinkedIn, Facebook, and Twitter.

Media Contact:
Adrienne Kim
Vested
917-765-8720
trintech@fullyvested.com

SOURCE: Trintech, Inc.

ReleaseID: 617208

GREENWOOD VILLAGE, CO / ACCESSWIRE / November 18, 2020 / Bio Lab Naturals, Inc. ("BLAB" or the "Company") (OTCQB:BLAB) announces today that its subsidiary, Prime Time Live, Inc. ("PTL") signed an Exclusive Distribution Agreement on November 13, 2020 with Insane Impact, LLC ("Insane Impact"), an Iowa limited liability company, to act as Insane Impact's exclusive distributor of Insane Impact Products. Insane Impact shall provide leads of LED screens for PTL sales and rentals to its customers.

Management Commentary
"This is a major day for our Company as we are now able to scale much faster and larger than expected. By using Insane Impact's extensive network, our Company is able to provide screens anywhere in the U.S. without spending the majority of our capital on equipment and overhead. Instead, our Company can now focus our resources on perfecting the marketing and broker model for these LED screens to a broader market. Another part of this Agreement that I am excited about is having Insane Impact's strong marketing capabilities to promote our 30' x 18' LED screen through their different channels. This will lead to more exposure for PTL," said Darrell Avey, CFO.

About Bio Lab Naturals, Inc.
Operating primarily through our subsidiary, Prime Time Live, Inc., is a Denver, CO based company that specializes in providing clients with high resolution mobile LED screens for entertainment, corporate, civic and sporting events. Our main operations are derived from our 30' x 18' LED mobile video display. This display is mounted in a 53 ft. trailer with an accompanying MQ Whisper Watt generator that can power the LED screen for 50 hours, and therefore, provides our clients with true portability. We also have an 8' x 5' mobile LED screen that is towed by a mid-size SUV. The 30' x 18' screen has a lifetime use of 50,000 hours of which 2,500 hours have been used and the 8' x 5' mobile LED screen is new with no hours.

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Bio Lab Naturals, Inc. undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact:
Bio Lab Naturals, Inc.
7400 E. Crestline Circle, Suite 130, Greenwood Village, CO 80111
(720) 273-0433
Website: https://primetimeliveevents.com/

SOURCE: Bio Lab Naturals, Inc.

ReleaseID: 617231

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform.

Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics' intranasal Covid-19 vaccine candidates in preclinical studies.

This new study will complement Mymetics' other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

EPALINGES, SWITZERLAND / ACCESSWIRE / November 18, 2020 / Mymetics SA, a subsidiary of Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, today announced that they have been awarded a grant from the Swiss Innovation Agency (Innosuisse). The grant will allow Mymetics in collaboration with the Department of Pneumology at the Inselspital, Bern University Hospital and the Department of Biomedical Research DBMR of Bern University to start a preclinical study which will investigate Mymetics' virosome-based Covid-19 nasal vaccine candidate for safety and tolerance, and its capacity to elicit protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.

Since April 2020, Mymetics' goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations. The Company is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens incorporated into virosome particles, while optimizing the route of administration and thermostability of the vaccine, before moving into human clinical trials.

With the nasal vaccine, Mymetics aims to elicit not only a systemic, but also a protective respiratory immunity with a local memory mucosal immunity, which is often poorly induced by standard intramuscular vaccination.

Prof. Thomas Geiser, the academic research leader of the project and Chairman and Chief Physician of Department of Pneumology at Inselspital, University Hospital Bern, is thankful for the committed research funding from Innosuisse: "We are confronted with an increasing number of Covid-19 patients and are very motivated to collaborate to the development of innovative vaccines. The research at the University Hospital in Bern receives a boost through this funding and recognizes the work of our research teams. The project with Mymetics will be performed at the Department for Biomedical Research (DBMR) of the University of Bern under supervision of Dr. Amiq Gazdar."

"This grant will allow us to evaluate our intranasal Covid-19 vaccine candidates, for which we aim to induce mucosal neutralizing antibodies and T cells as frontline defense to block SARS-CoV-2 aerosol transmission and nasal infection prior spreading to the lungs, brain and other organs" said Sylvain Fleury, Chief Scientific Officer of Mymetics.

"This Innosuisse funded, University Hospital and University of Bern collaboration is another example of our strategy to access expertise through collaborative approaches to advance towards a safe and highly efficacious Covid-19 virosome based vaccine," said Ronald Kempers, CEO of Mymetics. "We are grateful to the Innosuisse program and honored to have the opportunity to work with the team of University Hospital and University of Bern and believe their skills and expertise will bring valuable insights in our Covid-19 vaccine development."

About Mymetics

Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenza and malaria, and collaborative projects in the field of allergy immunotherapy and in oncology.

Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. For further information, please visit www.mymetics.com.

CONTACT:

Mymetics Corporation
Ronald Kempers, CEO
info@mymetics.com
Tel: +41 21 653 4535

Forward looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

SOURCE: Mymetics Corporation

ReleaseID: 617134

European clinical assessment of RLF-100(TM) for the treatment of COVID-19 induced lung injury planned to begin in Q1 2021

GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2020 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Syneos Health(R) (Nasdaq:SYNH), a leading global clinical research organization (CRO), to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications to be conducted in Europe. Relief has also selected AMRI, a global contract development and manufacturing organization (CDMO), who will provide aseptic fill/finish manufacturing of RLF-100TM at their Glasgow, UK, facility. European clinical assessment of RLF-100TM is slated to beginin Q1 2021.

Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, commented: "We are pleased to bring on board highly experienced service partners that are critical to successfully advancing our clinical development activities in Europe. As a global therapeutically aligned organization, Syneos Health(R) brings forward deep respiratory therapeutic expertise and the ability to activate clinical trials across multiple countries. AMRI's Glasgow team is a renowned global provider of contract manufacturing services and will support our sterile fill/finish drug product manufacturing needs. We believe these collaborations position Relief to develop RLF-100(TM) as quickly as possible in Europe."

###

ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100(TM) (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated, in cooperation with NeuroRx Inc., in two placebo-controlled U.S. Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100(TM) is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100(TM) under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100(TM).

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

CONTACT:
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
www.relieftherapeutics.com
Mail: contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG via EQS Newswire

ReleaseID: 617273

SINGAPORE / ACCESSWIRE / November 18, 2020 / Jadestone Energy Inc. (AIM:JSE)(TSXV:JSE)(OTC PINK:JADSF) ("Jadestone", or the "Company"), an independent oil and gas production company focused on the Asia Pacific region, announces the voluntary relinquishment and termination of Service Contract 56 ("SC56"), offshore Philippines.

Jadestone's wholly owned subsidiary Mitra Energy (Philippines SC-56) Ltd, together with operator Total E&P Philippines BV ("Total"), have notified the Philippines Department of Energy of their voluntary surrender of their entire interest in, and termination of, SC56.

Paul Blakeley, President and CEO commented:

"We remain focussed on our strategy of delivering value from producing fields and near-term developments in the Asia Pacific region, while avoiding early-phase greenfield exploration plays such as SC56, requiring multi-year capital programmes prior to production and cashflow. Nor would the major investments in new pipelines and facilities fit our sustainability objectives which include a focus on maximising use of existing infrastructure.

"SC56 was a legacy asset inherited from the previous management and only had option value through a carried well. The decision not to drill the well now removes any interest for Jadestone to continue further, requiring as it would, new deep-water frontier exploration commitments. It would also not compete with existing portfolio investment options, nor potentially some of the more interesting inorganic opportunities moving into the market in the coming 12 to 18 months.

"While we have appreciated great support and cooperation, and long association with the government and regulator in the Philippines, it is now time to relinquish our interest in SC56, as we continue to deploy our production optimisation and field-life extension skills across the region."

As a condition of the surrender and termination of SC56, the partners will be subject to a payment in respect of unfulfilled work commitments. Jadestone's share will be met from a portion of the proceeds of the arbitration ruling announced on January 9, 2020.

The Company also anticipates that it will record a one-time impairment charge of approximately US$50.5 million, relating to historical capitalised exploration expenditures on SC56 predominantly associated with previous management, with no associated cash impact or tax benefit.

– Ends –

Enquiries

Jadestone Energy Inc.

+65 6324 0359 (Singapore)

Paul Blakeley, President and CEO

+44 7392 940 495 (UK)

Dan Young, CFO

+1 403 975 6752 (Canada)

Robin Martin, Investor Relations Manager

ir@jadestone-energy.com

Stifel Nicolaus Europe Limited (Nomad, Joint Broker)

+44 (0) 20 7710 7600 (UK)

Callum Stewart

Simon Mensley

Ashton Clanfield

BMO Capital Markets Limited (Joint Broker)

+44 (0) 20 7236 1010 (UK)

Thomas Rider

Jeremy Low

Thomas Hughes

Camarco (Public Relations Advisor)

+44 (0) 203 757 4980 (UK)

Georgia Edmonds

jse@camarco.co.uk

Billy Clegg

James Crothers

About Jadestone Energy Inc.

Jadestone Energy Inc. is an independent oil and gas company focused on the Asia Pacific region. It has a balanced, low risk, full cycle portfolio of development, production and exploration assets in Australia, Vietnam and the Philippines.

The Company has a 100% operated working interest in the Stag oilfield and the Montara project, both offshore Australia. Both the Stag and Montara assets include oil producing fields, with further development and exploration potential. The Company has a 100% operated working interest in two gas development blocks in Southwest Vietnam.

In addition, the Company has executed a sale and purchase agreement to acquire an operated 69% interest in the Maari Project, shallow water offshore New Zealand, and anticipates completing the transaction in H2 2020, upon receipt of customary approvals. The Company has recently executed an agreement to acquire an operated 90% interest in the Lemang PSC, onshore Sumatra, Indonesia, and anticipates completing the transaction in Q1 2021, upon receipt of customary approvals. The block includes the Akatara gas field.

Led by an experienced management team with a track record of delivery, who were core to the successful growth of Talisman's business in Asia, the Company is pursuing an acquisition strategy focused on growth and creating value through identifying, acquiring, developing and operating assets in the Asia Pacific region.

Jadestone Energy Inc. is listed on the AIM market of the London Stock Exchange. The Company is headquartered in Singapore. For further information on Jadestone please visit www.jadestone-energy.com.

Cautionary statements

Certain statements in this press release are forward-looking statements and information (collectively "forward-looking statements"), within the meaning of the applicable Canadian securities legislation, as well as other applicable international securities laws. The forward-looking statements contained in this press release are forward-looking and not historical facts.

Some of the forward-looking statements may be identified by statements that express, or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of phrases such as "will likely result", "are expected to", "will continue", "is anticipated", "is targeting", "estimated", "intend", "plan", "guidance", "objective", "projection", "aim", "goals", "target", "schedules", and "outlook").

Because actual results or outcomes could differ materially from those expressed in any forward-looking statements, investors should not place undue reliance on any such forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes will not occur. Some of these risks, uncertainties and other factors are similar to those faced by other oil and gas companies and some are unique to Jadestone. The forward-looking information contained in this news release speaks only as of the date hereof. The Company does not assume any obligation to publicly update the information, except as may be required pursuant to applicable laws.

The information contained within this announcement is considered to be inside information prior to its release, as defined in Article 7 of the Market Abuse Regulation No. 596/2014, and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Jadestone Energy Inc.

ReleaseID: 617252

VANCOUVER, BC / ACCESSWIRE / November 18, 2020 / Grande West Transportation Group Inc. (TSXV:BUS)(OTCQX:GWTNF)(FRA:6LG) ("Grande West" or the "Company"), a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, is pleased to announce that, further to its news releases dated November 4, 2020, it has closed the first tranche of its $8M non-brokered private placement. The first tranche consisted of 7,816,118 Units raising gross proceeds of $7,816,118.

Each Unit consists of one common share of the Company and one-half of one share purchase warrant. Each whole warrant (a "Warrant") entitles the holder to acquire an additional common share of the Company at a price of $1.50 per share for a period of two years from the date of closing of the Placement.

In circumstances where, any time after the expiry of the four-month restricted period, the Company's stock trades at $1.75 or greater for 20 consecutive trading days, the Company may give notice accelerating the expiry date of the exercise period of the warrants to that date which is 30 days from the date of such notice.

Finder's fees of 6% cash and 6% Finder's warrants were payable in connection with the private placement, specifically: $126,900 and 126,900 warrants to PI Financial Corp.; $7,200 and 7,200 warrants to Haywood Securities Inc.; $36,600 and 36,600 warrants to Mackie Research Capital Corp.; $14,400 and 14,400 warrants to Raymond James Ltd. and $204,000 and 204,000 warrants to Leede Jones Gable Inc.

The securities issued in connection with the private placement are subject to a regulatory hold period expiring on March 18, 2021.

Proceeds from the Placement will be used for purchase of the Company's U.S. operations facility, new product development and certifications, new product demonstration models and working capital.

Directors and officers of the Company may acquire securities under the Placement, which participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). Such participation is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Grande West Transportation Group
Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built Vicinity heavy-duty bus available in clean diesel, gas and CNG drive systems. The Vicinity LT EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West's vehicles.

www.grandewest.com

For investor relations please contact:
Paradox Public Relations Inc.
Karl Mansour
Managing Director
Ph: (514) 341-0408 or 1-866-460-0408
IR@grandewest.com

Grande West Transportation
John LaGourgue
VP Corporate Development
Ph: 604-288-8043
IR@grandewest.com

Neither the TSX-V nor its Regulation Service Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding the use of proceeds from the Private Placement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause actual results to differ materially from Grande West's expectations include uncertainties relating to the receipt of final approval from the TSX-V; and other risk and uncertainties disclosed in Grande West's reports and documents filed with applicable securities regulatory authorities from time to time. Grande West's forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. Grande West assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: Grande West Transportation Group

ReleaseID: 617216

TORONTO, ON / ACCESSWIRE / November 17, 2020 / CordovaCann Corp. (CSE:CDVA) (OTCQB:LVRLF) ("Cordova" or the "Company"), a cannabis-focused consumer products company, is pleased to announce that its third Star Buds Cannabis Co. ("Star Buds") branded cannabis retail store in Ontario has received confirmation from the Alcohol and Gaming Commission of Ontario that it can open today. This store is located at 813 Innisfil Beach Road – Unit 1, in the city of Innisfil, and is operated by Cordova's subsidiary, 2734158 Ontario Inc. This Star Buds store will start processing online orders for in-store pickup from customers that are made through its website www.starbuds.co, and will also be open to walk-in customers starting today. The official grand opening of the store is scheduled for Friday November 20, 2020 and Saturday November 21, 2020.

Cordova is continuing its expansion plan by opening numerous Star Buds cannabis retail stores across Canada and expects to open additional stores in the coming weeks. The Company's first two stores continue to generate strong revenue and profits, giving the Company increased confidence in its retail business model in Canada. These stores have already generated over $1 million in revenues this quarter with a gross margin of 35%. This equates to a run rate of over $4 million in annual gross revenues per store, well above our initial expectations.

"We are excited to open Star Buds in Innisfil and believe this store will be one of the best in our retail store portfolio in Canada," stated Taz Turner, Chairman and CEO of Cordova. "I'm very pleased that we are accelerating the pace of store openings and we look forward to opening Star Buds stores in additional Canadian markets soon."

About CordovaCann Corp.

CordovaCann Corp. is a Canadian-domiciled company focused on building a leading, diversified cannabis products business across multiple jurisdictions including Canada and the United States. Cordova primarily provides services and investment capital to the retail, processing and production vertical markets of the cannabis industry.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" under the provisions of applicable Canadian securities legislation, concerning the business, operations and financial performance and condition of the Company. All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable Canadian securities laws, including statements with respect to the Company's planned business activities, the anticipated benefits of the opening of the store and the prospect of opening additional retail stores. Generally, this forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" , "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" , "believes", or variations or comparable language of such words and phrases or statements that certain actions, events or results "may", "could", "would", "should", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Forward-looking information is necessarily based upon a number of factors and assumptions that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements expressed or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including anticipated costs and ability to achieve business objectives and goals.

Certain important factors that could cause actual results, performances or achievements to differ materially from those in the forward-looking information including but not limited to: global economic and market conditions; the war on terrorism and the potential for war or other hostilities in other parts of the world; the availability of financing and lines of credit; successful integration of acquired or merged businesses; changes in interest rates; management's ability to forecast revenues and control expenses, especially on a quarterly basis; unexpected decline in revenues without a corresponding and timely slowdown in expense growth; the Company's ability to retain key management and employees; intense competition and the Company's ability to meet demand at competitive prices and to continue to introduce new products and new versions of existing products that keep pace with technological developments, satisfy increasingly sophisticated customer requirements and achieve market acceptance; relationships with significant suppliers and customers; as well as other risks and uncertainties, including but not limited to those detailed from time to time in the Company's public filings on EDGAR and SEDAR. Although the Company believes its expectations are based upon reasonable assumptions and has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company provides forward-looking information for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are made as of the date hereof and, accordingly, are subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by applicable law.

Company Contact:

Taz Turner
Chief Executive Officer
taz@cordovacann.com
(917) 843-2169

SOURCE: CordovaCann Corp.

ReleaseID: 617116

The Michael Shah Scholarship Program is now accepting submissions from post-secondary and soon-to-be post-secondary students who require financial assistance in pursuit of their academic goals and dreams.

NEW YORK, NY / ACCESSWIRE / November 17, 2020 / Competition is now open and underway for the four financial prizes offered by the newly-established Michael Shah Scholarship Program. Three prizes of one thousand dollars and one prize of two thousand dollars will soon be released to four worthy students, pending judgment of their applications.

The Michael Shah Scholarship Program was created to encourage and give aid to promising, hard-working students who have been disproportionately affected by the recent economic downturn prompted by the COVID-19 pandemic. The outbreak and spread of COVID-19 has caused unemployment rates to rise precipitously in the United States and Canada over the last nine months, causing substantial financial hardships for high school and post-secondary students who are often the first to lose their jobs. The Michael Shah Scholarship Program recognizes that, for a great deal of students, pursuing an academic career without some kind of employment or access to a steady income is a near-impossibility. After all, tuition, lodgings, and course materials are far from inexpensive. The financial prizes offered by the Michael Shah Scholarship Program aim to mitigate these costs, if only partially.

Outside of producing a formal letter of acceptance from a legitimately recognized institution of higher learning, all entrants have to do in order to qualify for the prizes is compose a five hundred word essay that meets two simple criteria. First, it must explicitly demonstrate the student's need for financial assistance. Second, it must detail an intended long-term career path after graduation. The competition is open to all post-secondary students studying within North America. The deadline for applications is February 28, 2021.

Good luck to all those who apply!

michaelshahscholarship.com

About Michael Shah

Michael Shah is the founder and CEO of DelShah Capital, LLC.

Long an enthusiastic proponent of higher education, Michael attended Harvard University, where he graduated magna cum laude, earning a bachelor's degree in chemistry. From there, he went on to earn a master's degree in finance and economics from the London School of Economics, only to return to Harvard, this time to study law, ultimately placing first in his graduating class. Michael Shah has received numerous awards for academic achievement, including the Sears Prize in both 2001 and 2002, and the Fay Diploma in 2003.

Upon entering the professional world, Michael Shah joined the mergers and acquisitions division of the law firm Wachtel, Lipton, Rosen & Katz based out of New York City. Here, he specialized in handling negotiations and bankruptcies, as well as overseeing complex deal structuring. In 2006, Michael Shah decided to break out on his own. He refinanced and recapitalized his family's Park Hill apartment complex to create over twenty million dollars in operating capital, which was more than enough to finance the establishment of his own company: DelShah Capital, a vertically-integrated real estate, private equity, and asset management firm. Since its inception, DelShah Capital has consistently produced superlative risk-adjusted returns through intelligent investment in residential, commercial, and mixed-use real estate.

Contact

Michael Shah
Founder of DelShah Capital, LLC
michael@delshah.com
+1 (917) 522-6705 (o)

SOURCE: Michael Shah

ReleaseID: 617118